Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short-term Investments: 2009-2025

Historic Short-term Investments for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $737.1 million.

  • Cytokinetics' Short-term Investments fell 23.60% to $737.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.1 million, marking a year-over-year decrease of 23.60%. This contributed to the annual value of $981.2 million for FY2024, which is 95.53% up from last year.
  • Cytokinetics' Short-term Investments amounted to $737.1 million in Q3 2025, which was down 5.89% from $783.2 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Short-term Investments registered a high of $981.2 million during Q4 2024, and its lowest value of $313.1 million during Q2 2021.
  • For the 3-year period, Cytokinetics' Short-term Investments averaged around $699.7 million, with its median value being $737.1 million (2025).
  • Per our database at Business Quant, Cytokinetics' Short-term Investments spiked by 122.89% in 2021 and then slumped by 42.27% in 2023.
  • Quarterly analysis of 5 years shows Cytokinetics' Short-term Investments stood at $359.0 million in 2021, then soared by 99.74% to $717.0 million in 2022, then crashed by 30.01% to $501.8 million in 2023, then soared by 95.53% to $981.2 million in 2024, then decreased by 23.60% to $737.1 million in 2025.
  • Its last three reported values are $737.1 million in Q3 2025, $783.2 million for Q2 2025, and $864.5 million during Q1 2025.